title: The treatment of recurrent central serous chorioretinopathy with intravitreal bevacizumab.
abstract: OBJECTIVE
  To study the effect of intravitreal bevacizumab injection in recurrent central serous chorioretinopathy (CSC).
  
  
  METHODS
  Retrospective case series. Patients followed at the Yale Eye Center with a diagnosis of recurrent CSC who were treated with intravitreal bevacizumab from January 2007 to January 2009 were studied. Intravitreal injections of bevacizumab were given once every 4 weeks until sub-retinal fluid resolved. We collected preinjection visual acuity, optical coherence tomography (OCT), fluorescein angiography imaging, number of injections administered, OCT data after each injection, and visual acuity after each injection. Each patient was followed for a minimum of 6 months.
  
  
  RESULTS
  Three patients met the inclusion criteria. All patients were men and aged from 39 to 46 years. All patients had recurrent disease. None had received prior treatment. Mean preinjection visual acuity was logMar 0.30, with a median of 0.30. Mean postbevacizumab visual acuity was 0.03, 0.07, and 0.03 at 1, 3, and 6 months, respectively. Median postbevacizumab acuity was 0, 0.10, and 0 at 1, 3, and 6 months, respectively. Baseline preinjection central macular thickness (CMT) by OCT imaging ranged from 320 to 500 μm, with a mean of 388 μm and a median of 344 μm. Mean CMT at month 1 was 248 μm, with a median of 190 μm. Mean CMT at month 3 was 252 μm, with a median of 281 μm. Mean CMT at month 6 was 273 μm, with a median of 187 μm.
  
  
  CONCLUSIONS
  Bevacizumab may be an effective treatment option for patients with recurrent CSC. Although long-term efficacy is unknown, it is a relatively low-risk treatment option that may improve visual acuity and CMT.
authors.affiliation: Department of Ophthalmology and Visual Science, Yale University School of Medicine, New Haven, Connecticut 06510, USA.
authors.forename: Shelly T
authors.initials: ST
authors.lastname: Lee
authors.forename: Ron A
authors.initials: RA
authors.lastname: Adelman
mesh_terms: D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D056833:Central Serous Chorioretinopathy / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D055502:Secondary Prevention; D041623:Tomography, Optical Coherence; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000187:drug effects
chemical_list: D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab